Literature DB >> 14991939

Effects of tumor necrosis factor, endothelin and nitric oxide on hyperdynamic circulation of rats with acute and chronic portal hypertension.

Ji-Jian Wang1, Gen-Wu Gao, Ren-Zhong Gao, Chang-An Liu, Xiong Ding, Zhen-Xiang Yao.   

Abstract

AIM: To evaluate the effect of tumor necrosis factor (TNF), endothelin (ET) and nitric oxide (NO) on hyperdynamic circulation (HC) of rats with acute and chronic portal hypertension (PHT).
METHODS: Chronic portal hypertension was induced in Wistar rats by injection of carbon tetrachloride. After two weeks of cirrhosis formation, L-NMMA (25 mg/kg) was injected into one group of cirrhotic rats via femoral vein and the experiment was begun immediately. Another group of cirrhotic rats was injected with anti-rat TNFalpha (300 mg/kg) via abdominal cavity twice within 48 h and the experiment was performed 24 h after the second injection. The blood concentrations of TNFalpha, ET-1 and NO in portal vein and the nitric oxide synthase (NOS) activity in hepatic tissue were determined pre-and post-injection of anti-rat TNFalpha or L-NMMA. Stroke volume (SV), cardiac output (CO), portal pressure (PP), superior mesenteric artery blood flow (SMA flow) and iliac artery blood flow (IAflow) were measured simultaneously. Acute portal hypertension was established in Wistar rats by partial portal-vein ligation (PVL). The parameters mentioned above were determined at 0.5 h, 24 h, 48 h, 72 h and 120 h after PVL. After the formation of stable PHT, the PVL rats were injected with anti-rat TNFalpha or L-NMMA according to different groups, the parameters mentioned above were also determined.
RESULTS: In cirrhotic rats, the blood levels of TNFalpha, NO in portal vein and the liver NOS activity were significantly increased (P<0.05) while the blood level of ET-1 was not statistically different (P>0.05) from the control animals (477.67+/-83.81 pg/mL vs 48.87+/-32.79 pg/mL, 278.41+/-20.11 micromol/L vs 113.28+/-14.51 micromol/L, 1.81+/-0.06 u/mg.prot vs 0.87+/-0.03 u/mg.prot and 14.33+/-4.42 pg/mL vs 8.72+/-0.79 pg/mL, respectively). After injection of anti-rat TNFalpha, the blood level of TNFalpha was lower than that in controls (15.17+/-18.79 pg/mL vs 48.87+/-32.79 pg/mL). The blood level of NO and the liver NOS activity were significantly decreased, but still higher than those of the controls. The blood level of ET-1 was not significantly changed. PP, SV, CO, SMAflow and IAflow were ameliorated. After injection of L-NMMA, the blood level of NO and the liver NOS activity were recovered to those of the controls. PP and CO were also recovered to those of the controls. SV, SMAflow and IAflow were ameliorated. In PVL rats, the blood levels of TNFalpha, NO in portal vein and the liver NOS activity were gradually increased and reached the highest levels at 48 h after PVL. The blood level of ET-1 among different staged animals was not significantly different from the control animals. PP among different staged animals (2.4+/-0.18 kPa at 0.5 h, 1.56+/-0.08 kPa at 24 h, 1.74+/-0.1 kPa at 48 h, 2.38+/-0.05 kPa at 72 h, 2.39+/-0.16 kPa at 120 h) was significantly higher than that in controls (0.9+/-0.16 kPa). After injection of anti-rat TNFalpha in 72 h PVL rats, the blood level of TNFalpha was lower than that in controls (14+/-14 pg/mL vs 48.87+/-32.79 pg/mL). The blood level of NO and the liver NOS activity were significantly decreased, but still higher than those of the controls. The blood level of ET-1 was not significantly changed. PP was decreased from 2.38+/-0.05 kPa to 1.68+/-0.12 kPa, but significantly higher than that in controls. SV, CO, SMAflow and IAflow were ameliorated. After injection of L-NMMA in 72 h PVL rats, the blood level of NO and the liver NOS activity were recovered to those of the controls. PP, SV, CO, SMAflow and IAflow were also recovered to those of the controls.
CONCLUSION: NO plays a critical role in the development and maintenance of HC in acute PHT and is a key factor for maintenance of HC in chronic PHT. TNFalpha may not participate in the hemodynamic changes of HC directly, while play an indirect role by inducing the production of NO through activating NOS. No evidence that circulating ET-1 plays a role in both models of portal hypertension has been found.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991939      PMCID: PMC4716910          DOI: 10.3748/wjg.v10.i5.689

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

1.  Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance.

Authors:  H Kojima; J Yamao; T Tsujimoto; M Uemura; A Takaya; H Fukui
Journal:  J Hepatol       Date:  2000-01       Impact factor: 25.083

2.  Effects of somatostatin on splanchnic hemodynamics in cirrhotic patients with portal hypertension.

Authors:  Ji-Ye Zhu; Xi-Sheng Leng; Dong Wang; Ru-Yu Du
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

3.  Type A, but not type B, endothelin receptor antagonists significantly decrease portal pressure in portal hypertensive rats.

Authors:  A De Gottardi; S Shaw; H Sägesser; J Reichen
Journal:  J Hepatol       Date:  2000-11       Impact factor: 25.083

4.  Effects of selective nitric oxide synthase inhibition in hyperdynamic endotoxemia in dogs.

Authors:  A Wolfárd; J Kaszaki; C Szabó; Z Balogh; S Nagy; M Boros
Journal:  Eur Surg Res       Date:  1999       Impact factor: 1.745

5.  Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis.

Authors:  N Nagasue; D K Dhar; A Yamanoi; Y Emi; J Udagawa; A Yamamoto; M Tachibana; H Kubota; H Kohno; T Harada
Journal:  Hepatology       Date:  2000-05       Impact factor: 17.425

6.  Endothelin-1 plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B together with subtype A in vivo.

Authors:  H Kojima; S Sakurai; S Kuriyama; H Yoshiji; H Imazu; M Uemura; Y Nakatani; J Yamao; H Fukui
Journal:  J Hepatol       Date:  2001-06       Impact factor: 25.083

7.  [Dexamethasone, an inhibitor of the expression of inducible nitric oxide synthase, does not modify the hyperdynamic state in cirrhotic rats].

Authors:  L Albornoz; J C Bandi; M de las Heras; R Mastai
Journal:  Medicina (B Aires)       Date:  2000       Impact factor: 0.653

8.  Endothelin-1 induces vasoconstriction on portal-systemic collaterals of portal hypertensive rats.

Authors:  C C Chan; S S Wang; F Y Lee; F Y Chang; H C Lin; C J Chu; C T Chen; H C Huang; S D Lee
Journal:  Hepatology       Date:  2001-04       Impact factor: 17.425

9.  Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal-hypertensive rats.

Authors:  L A Colombato; A Albillos; R J Groszmann
Journal:  Hepatology       Date:  1992-02       Impact factor: 17.425

10.  Altered endothelin receptor expression in prehepatic portal hypertension predisposes the liver to microcirculatory dysfunction in rats.

Authors:  Y Yokoyama; A Wawrzyniak; R Baveja; N Sonin; M G Clemens; J X Zhang
Journal:  J Hepatol       Date:  2001-07       Impact factor: 25.083

View more
  9 in total

1.  Selective Intestinal Decontamination in Portal Hypertension.

Authors:  William Kemp; Jaye Chin-Dusting
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-01

2.  Morphological and biomechanical remodelling of the hepatic artery in a swine model of portal hypertension.

Authors:  Xi-Ju He; Ming-Hua Yu; Wen-Chun Li; Han-Qin Wang; Jing Li; Xing-Chun Peng; Jie Tang; Na Feng; Tie-Zhu Huang
Journal:  Hepatol Int       Date:  2011-09-23       Impact factor: 6.047

3.  Thalidomide ameliorates portal hypertension via nitric oxide synthase independent reduced systolic blood pressure.

Authors:  Nicholas G Theodorakis; Yining N Wang; Vyacheslav A Korshunov; Mary A Maluccio; Nicholas J Skill
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

4.  Murine study of portal hypertension associated endothelin-1 hypo-response.

Authors:  Nicholas Theodorakis; Mary Maluccio; Nicholas Skill
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

5.  Systemic and pulmonary hemodynamics in patients with extrahepatic portal vein obstruction is similar to compensated cirrhotic patients.

Authors:  Sanjeev Kumar Jha; Ashish Kumar; Barjesh Chander Sharma; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2008-12-06       Impact factor: 6.047

6.  Tumor necrosis factor alpha signaling in the development of experimental murine pre-hepatic portal hypertension.

Authors:  Nicholas G Theodorakis; Yining N Wang; Jianmin Wu; Mary A Maluccio; Nicholas J Skill
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2010-03-08

7.  Partial portal vein ligation plus thioacetamide: a method to obtain a new model of cirrhosis and chronic portal hypertension in the rat.

Authors:  Marta Méndez-López; Magdalena Méndez; Fernando Sánchez-Patán; Isabel Casado; Maria-Angeles Aller; Laudino López; Maria-Teresa Corcuera; Maria-Jose Alonso; Maria-Paz Nava; Jaime Arias; Jorge-Luis Arias
Journal:  J Gastrointest Surg       Date:  2007-02       Impact factor: 3.452

8.  Effect of Prometheus liver assist system on systemic hemodynamics in patients with cirrhosis: a randomized controlled study.

Authors:  Thomas Dethloff; Flemming Tofteng; Hans-Jorgen Frederiksen; Michael Hojskov; Bent-Adel Hansen; Fin-Stolze Larsen
Journal:  World J Gastroenterol       Date:  2008-04-07       Impact factor: 5.742

9.  Vascular stasis, intestinal hemorrhage, and heightened vascular permeability complicate acute portal hypertension in cd39-null mice.

Authors:  Xiaofeng Sun; Andrés Cárdenas; Yan Wu; Keichi Enjyoji; Simon C Robson
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-06-11       Impact factor: 4.052

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.